Skip to main
TOI
TOI logo

TOI Stock Forecast & Price Target

TOI Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

The Oncology Institute Inc. is strategically positioned for future growth as indicated by its strong revenue growth rates of 24%, 28%, and 21% year-over-year from 2022 to 2024, driven by an increased number of clinics under management. The anticipated partnership with Helios is expected to enhance margins significantly by 2026 and 2027, further supported by the overall growth in the U.S. oncology market projected at a 10%+ CAGR. Additionally, the company's focus on expanding its dispensary segment and bolstering its presence in high-value markets like Nevada and Florida contributes to a positive long-term outlook for earnings and sustainable growth.

Bears say

The Oncology Institute Inc. has recently experienced significant declines in revenue contribution, particularly with HUM's share dropping from 20% to less than 10%. Furthermore, the company's gross margins have been negatively impacted by contract losses in 2024, combined with heightened pressures as new contracts are anticipated to scale in the upcoming years. The operational challenges are compounded by decreasing dispensary margins due to the elimination of DIR fees and a stagnant growth trend in patient services that is well below the industry average.

TOI has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of The Oncology Institute and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About The Oncology Institute (TOI) Forecast

Analysts have given TOI a Strong Buy based on their latest research and market trends.

According to 3 analysts, TOI has a Strong Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

The Oncology Institute (TOI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.